产品
编 号：F495678
分子式：C21H20FN3O6S
分子量：461.46
分子式：C21H20FN3O6S
分子量：461.46
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
200
In-stock
500mg
400
In-stock
结构图
CAS No: 881681-01-2
产品详情
生物活性：
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
体内研究：
Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (2DG, 200 mg/kg s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats.Animal Model:Male 7- or 8-week-old Sprague-Dawley rat
Dosage:0.5, 1, 2, and 4 mg/kg
Administration:Oral administration
Result:Inhibited basal gastric acid secretion in a dose-dependent manner.
体外研究：
Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner.Vonoprazan does not inhibit Na+,K+-ATPase activity, even at concentrations 500 times higher than their IC50 values against gastric H+,K+-ATPase activity.
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
体内研究：
Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (2DG, 200 mg/kg s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats.Animal Model:Male 7- or 8-week-old Sprague-Dawley rat
Dosage:0.5, 1, 2, and 4 mg/kg
Administration:Oral administration
Result:Inhibited basal gastric acid secretion in a dose-dependent manner.
体外研究：
Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner.Vonoprazan does not inhibit Na+,K+-ATPase activity, even at concentrations 500 times higher than their IC50 values against gastric H+,K+-ATPase activity.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备